Published in Blood Weekly, March 6th, 1995
Recent advances in technology and new insights into HIV pathogenesis have led to the collection and interpretation of virologic data in ACTG studies.
In a plenary address to the ACTG, Harvard researcher Clyde Crumpacker reported analyses of such data obtained in the ACTG 116A clinical trial, which compared AZT monotherapy to ddI monotherapy. Crumpacker's address represents the first report of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.